Mesenchymal stem cells for treatment of musculoskeletal disease in horses: Relative merits of allogeneic versus autologous stem cells.
Authors: Colbath Aimée C, Dow Steven W, McIlwraith C Wayne, Goodrich Laurie R
Journal: Equine veterinary journal
Summary
# Editorial Summary Mesenchymal stem cell (MSC) therapy has become commonplace in equine practice for musculoskeletal injuries, yet clinicians continue to debate whether allogeneic cells (from donor horses) offer comparable safety and efficacy to autologous cells (harvested from the treated horse). Colbath and colleagues reviewed published evidence comparing these two approaches, examining immunological concerns, cell survival rates, and practical advantages including the ability to bank and prepare allogeneic cells in advance of treatment. Early in vitro and experimental in vivo studies raised concerns about immune rejection of allogeneic MSCs in horses, but more recent clinical research has largely failed to demonstrate inflammatory reactions or adverse outcomes when allogeneic cells are used, with results comparable to autologous therapy. The evidence base, whilst promising, remains limited; the authors call for large-scale randomised controlled trials with rigorous immunological monitoring to definitively establish whether allogeneic MSCs represent a viable alternative that could streamline treatment protocols and reduce costs through cell banking and batch preparation. For practitioners considering MSC therapy, this review indicates allogeneic products warrant serious consideration, particularly where the logistical advantages of pre-prepared cells and reduced treatment delay may benefit patient welfare.
Read the full abstract on PubMed
Practical Takeaways
- •Allogeneic MSCs appear to be a safe treatment alternative to autologous MSCs for equine musculoskeletal injuries based on emerging evidence, potentially offering faster treatment availability
- •Banked allogeneic cell products could reduce the interval between injury diagnosis and treatment initiation compared to autologous MSC harvesting
- •Current evidence does not clearly support one approach over the other; treatment choice should consider individual case factors, cell availability, and cost until larger definitive trials are completed
Key Findings
- •In vitro and early in vivo studies showed potential for adverse immunological reactions with allogeneic MSCs in horses, but newer studies lack evidence of inflammatory reactions or adverse clinical responses
- •Allogeneic MSCs offer practical advantages including cell banking, reduced time to treatment, use of younger donor animals, and pre-treatment cell manipulation
- •Autologous MSCs remain widely used despite requiring longer collection times and individual cell harvest procedures
- •Large randomised controlled trials with detailed immunological evaluation are needed to definitively establish the relative safety and efficacy of allogeneic versus autologous MSCs